[HTML][HTML] Approved HIV reverse transcriptase inhibitors in the past decade

G Li, Y Wang, E De Clercq - Acta Pharmaceutica Sinica B, 2022 - Elsevier
HIV reverse transcriptase (RT) inhibitors are the important components of highly active
antiretroviral therapies (HAARTs) for anti-HIV treatment and pre-exposure prophylaxis in …

Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: a systematic literature …

S Kanters, M Vitoria, M Zoratti, M Doherty… - …, 2020 - thelancet.com
Abstract Background To inform World Health Organization (WHO) global guidelines, we
updated and expanded the evidence base to assess the comparative efficacy, tolerability …

Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society–USA panel

RT Gandhi, R Bedimo, JF Hoy, RJ Landovitz, DM Smith… - Jama, 2023 - jamanetwork.com
Importance Recent advances in treatment and prevention of HIV warrant updated
recommendations to guide optimal practice. Objective Based on a critical evaluation of new …

Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society–USA Panel

MS Saag, CA Benson, RT Gandhi, JF Hoy… - Jama, 2018 - jamanetwork.com
Importance Antiretroviral therapy (ART) is the cornerstone of prevention and management of
HIV infection. Objective To evaluate new data and treatments and incorporate this …

Doravirine/lamivudine/tenofovir disoproxil fumarate is non-inferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults with human …

C Orkin, KE Squires, JM Molina, PE Sax… - Clinical Infectious …, 2019 - academic.oup.com
Background Doravirine (DOR), a novel non-nucleoside reverse-transcriptase inhibitor
(NNRTI), is active against wild-type Human Immunodeficiency Virus (HIV)-1 and the most …

[HTML][HTML] 2019 update of the drug resistance mutations in HIV-1

AM Wensing, V Calvez… - Topics in antiviral …, 2019 - ncbi.nlm.nih.gov
The 2019 edition of the IAS-USA drug resistance mutations list updates the Figure last
published in January 2017. The mutations listed are those that have been identified by …

The journey of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) from lab to clinic

V Namasivayam, M Vanangamudi… - Journal of medicinal …, 2018 - ACS Publications
Human immunodeficiency virus (HIV) infection is now pandemic. Targeting HIV-1 reverse
transcriptase (HIV-1 RT) has been considered as one of the most successful targets for the …

Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal …

A Mocroft, JD Lundgren, M Ross, CA Fux, P Reiss… - The lancet HIV, 2016 - thelancet.com
Background Whether or not the association between some antiretrovirals used in HIV
infection and chronic kidney disease is cumulative is a controversial topic, especially in …

Contemporary medicinal chemistry strategies for the discovery and development of novel HIV-1 non-nucleoside reverse transcriptase inhibitors

Z Wang, S Cherukupalli, M Xie, W Wang… - Journal of Medicinal …, 2022 - ACS Publications
Currently, HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a major
component of the highly active anti-retroviral therapy (HAART) regimen. However, the …

Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment

Y Wang, E De Clercq, G Li - Expert opinion on drug metabolism & …, 2019 - Taylor & Francis
Introduction: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are essential
components of highly active antiretroviral therapy against HIV-1 infections. Here, we provide …